Journal article
A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects
Abstract
OBJECTIVE: Effectively evaluating disease-modifying effects in clinical trials has posed a problem for clinical trialists and drug development. One method that has been proposed to evaluate disease-modifying effects has been the re-randomization of active group participants to discontinue the intervention after a period sufficient to produce therapeutic effects. We aimed to determine if this design would permit inferences regarding disease …
Authors
Mills E; Heels-Ansdell D; Kelly S; Guyatt G
Journal
Journal of Clinical Epidemiology, Vol. 60, No. 5, pp. 456–460
Publisher
Elsevier
Publication Date
5 2007
DOI
10.1016/j.jclinepi.2006.09.001
ISSN
0895-4356